Adjuvant tamoxifen adherence in male patients with breast cancer : An ongoing challenge
| Errataetall: | |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:128 |
|---|---|
| Enthalten in: |
Cancer - 128(2022), 1 vom: 01. Jan., Seite 22-24 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Falkson, Carla I [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
094ZI81Y45 |
|---|
| Anmerkungen: |
Date Completed 09.03.2022 Date Revised 09.03.2022 published: Print-Electronic CommentOn: Cancer. 2022 Jan 1;128(1):59-64. - PMID 34597415 Citation Status MEDLINE |
|---|
| doi: |
10.1002/cncr.33898 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM331388200 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM331388200 | ||
| 003 | DE-627 | ||
| 005 | 20231225213342.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/cncr.33898 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1104.xml |
| 035 | |a (DE-627)NLM331388200 | ||
| 035 | |a (NLM)34597416 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Falkson, Carla I |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Adjuvant tamoxifen adherence in male patients with breast cancer |b An ongoing challenge |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 09.03.2022 | ||
| 500 | |a Date Revised 09.03.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentOn: Cancer. 2022 Jan 1;128(1):59-64. - PMID 34597415 | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Editorial | |
| 650 | 4 | |a Comment | |
| 650 | 4 | |a adjuvant endocrine therapy | |
| 650 | 4 | |a adjuvant tamoxifen | |
| 650 | 4 | |a discontinuing treatment | |
| 650 | 4 | |a drug adherence | |
| 650 | 4 | |a male breast cancer | |
| 650 | 7 | |a Antineoplastic Agents, Hormonal |2 NLM | |
| 650 | 7 | |a Tamoxifen |2 NLM | |
| 650 | 7 | |a 094ZI81Y45 |2 NLM | |
| 773 | 0 | 8 | |i Enthalten in |t Cancer |d 1948 |g 128(2022), 1 vom: 01. Jan., Seite 22-24 |w (DE-627)NLM000028649 |x 1097-0142 |7 nnns |
| 773 | 1 | 8 | |g volume:128 |g year:2022 |g number:1 |g day:01 |g month:01 |g pages:22-24 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/cncr.33898 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 128 |j 2022 |e 1 |b 01 |c 01 |h 22-24 | ||